CYTK | tickerfilter.com

Fundamental analysis

41%

Profitability 25%

Dept financing 39%

Liquidity 50%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.37%

1 Month

3.37%

3 Months

-5.18%

6 Months

17.47%

1 Year

41.91%

2 Year

-6.26%

Key data

Stock price

$62.27

P/E Ratio

0.00

DAY RANGE

$60.01 - $62.57

EPS

-$6.54

52 WEEK RANGE

$29.31 - $70.98

52 WEEK CHANGE

$43.91

MARKET CAP

7.769 B

YIELD

N/A

SHARES OUTSTANDING

123.163 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,204,642

AVERAGE 30 VOLUME

$1,892,759

Company detail

CEO: Robert I. Blum
Region: US
Website: cytokinetics.com
Employees: 250
IPO year: 2004

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cytokinetics, Incorporated focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.

CYTK - CYTOKINETICS INC